All AbMole products are for research use only, cannot be used for human consumption.
ART26.12 is a potent, selective, orally active inhibitor of Fatty Acid Binding Protein 5 (FABP5). ART26.12 regulates lipid metabolism and activates cannabinoid receptors to alleviate oxaliplatin-induced pain.
ART26.12 (25-100mg/kg; oral; twice daily; 10 days) decreased the severity of symptoms such as hyperkeratosis, parakeratosis, epidermal acanthosis, and inflammatory infiltration. ART26.12 (25-100 mg/kg; oral; single dose) significantly increased the paw withdrawal threshold (PWT) for mechanical allodynia at 30 minutes to 8 hours post-dose, with the effect dependent on CB1 receptor and potentially involving CB2, TRPV1, and PPARα antagonists.
| Molecular Weight | 472.53 |
| Formula | C29H28O6 |
| CAS Number | 2766800-24-0 |
| Form | Solid |
| Solubility (25°C) | DMSO 95 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related FABP Products |
|---|
| a-FABP-IN-1
a-FABP-IN-1 is a potent and selective human adipocyte fatty acid-binding protein (a-FABP) inhibitor with a Ki below 1.0 nM. |
| CooP
CooP is a linear glioblastoma-targeting nonapeptide. |
| FABP4-IN-2
FABP4-IN-2 is a selective and orally active FABP4 inhibitor with the Ki values of 0.51 μM for FABP4, 33.01 μM for FABP3. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
